Tempus AI logo

Tempus AI

TEM | NASDAQ
Chart Builder DCF Calculator
$64.76
-$6.84 (-9.55%)
At close: Nov 16, 2026, 4:00 PM ET
$66.85
+$2.09 (+3.23%)
After-hours: Nov 16, 2026, 7:59 PM ET
-9.55%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
50.5
Fundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #279/1021 (Top 27%)

Key Statistics

Market Data

Market Cap $11.49B
1D Range
64.57 69.22
52W Range
41.55 85.08

Valuation (TTM)

PE -61.09
PB 22.95
EV/EBITDA -388.30

Valuation (NTM)

Forward PE 6,381.00
Forward PEG 0.74
Price Target $78.00
Loading financial charts...

Profile

Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop an...

Sector Healthcare
Employees 3,800
IPO Date Jun 14, 2024
Fiscal Year January - December

Latest News

Arizona Eagle Mining Corp. Announces Completion of High Resolution TEM Geophysical Survey at the Eagle Project and Provides Update on McCabe Mine Reopening Studies

4 days ago · newsfilecorp.com

Arizona Eagle Mining Corp. Announces Completion of High Resolution TEM Geophysical Survey at the Eagle Project and Provides Update on McCabe Mine Reopening Studies
Tempus to Present Six Abstracts Accepted at the 2026 Connective Tissue Oncology Society Annual Meeting

5 days ago · businesswire.com

Tempus to Present Six Abstracts Accepted at the 2026 Connective Tissue Oncology Society Annual Meeting
Blood Cancer United Launches REALworld: AML to Accelerate New Treatments for Children with Blood Cancer

6 days ago · prnewswire.com

Blood Cancer United Launches REALworld: AML to Accelerate New Treatments for Children with Blood Cancer
SOTERIA Collaborates with Tempus to Advance Precision Oncology for U.S. Military and Veterans Battling Cancer

7 days ago · prnewswire.com

SOTERIA Collaborates with Tempus to Advance Precision Oncology for U.S. Military and Veterans Battling Cancer
Tempus AI: Q3 Strengthens The Platform Thesis, But Cash Returns Still Need To Catch Up

9 days ago · seekingalpha.com

Tempus AI: Q3 Strengthens The Platform Thesis, But Cash Returns Still Need To Catch Up
Tempus AI: An Inflection Point Has Arrived (Earnings Analysis)

13 days ago · seekingalpha.com

Tempus AI: An Inflection Point Has Arrived (Earnings Analysis)
Tempus AI Surges on Earnings Beat, But Can the Rally Last?

14 days ago · marketbeat.com

Tempus AI Surges on Earnings Beat, But Can the Rally Last?
TEM Q3 Earnings Call Highlights Growth and 2027 Pricing Upside

14 days ago · zacks.com

TEM Q3 Earnings Call Highlights Growth and 2027 Pricing Upside
Tempus AI Analysts Boost Their Forecasts Following Strong Q3 Results

14 days ago · benzinga.com

Tempus AI Analysts Boost Their Forecasts Following Strong Q3 Results
Do You Own Tempus AI Without Knowing It? Check These ETFs After Its Earnings Surge

14 days ago · 247wallst.com

Do You Own Tempus AI Without Knowing It? Check These ETFs After Its Earnings Surge

Earnings

Latest Earnings
Nov 2, 2026
EPS
$0.07
Beat +174.71%
REV
$411.54M
Beat +0.52%
Next Earnings
Feb 23, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
14
Consensus
Buy
Price Target
$78.00
Upside
+20.44%
Buy (10)
Hold (4)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.